Trial · NCT07493148
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
NCT07493148, Phase 2, Recruiting, Ou Bai, MD/PHD
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL. Trials, record NCT07493148. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07493148
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
- NCT number
- NCT07493148
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Ou Bai, MD/PHD
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Chidamide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Chidamide + Rituximab maintenance
- First posted
- 2026-03-25
- Last updated
- 2026-03-25
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | 24 months | The time from study enrollment to the first documented disease progression or death from any cause, whichever occurs first. |
| Secondary | Overall Response Rate (ORR) | 24 months | To assess the Overall Response Rate (ORR) referred to Lugano 2014. |
| Secondary | Duration of Response (DOR) | 24 months | The duration from the first documentation of response (achievement of complete response or partial response) to the first unequivocal evidence of relapse or progression. |
| Secondary | Complete Response Rate (CRR) | 24 months | To assess the Complete Response Rate (CRR) referred to Lugano 2014. |
| Secondary | Percentage of patients converting from PR/SD to CR/PR | 24 months | Percentage of patients converting from PR/SD to CR/PR |
| Secondary | Overall survival（OS） | 24 months | Overall survival（OS） is defined as the time from the date of enrollment to the date of death from any cause. |
| Secondary | Adverse Events | 24 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment, assessed by NCI-CTCAE v5.0. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. |
| Other | Biomarker exploration | 24 months | ctDNA testing will be performed at baseline, after 6 cycles of treatment, every 6 months during the maintenance period, and at disease progression or study withdrawal, to evaluate the correlation between ctDNA and treatment efficacy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07493148
GET https://conductscience.org/api/trials/v1/NCT07493148/registered